444
H. Jin
Table 14.4
(continued)
Molecular
target
Aptamer
Sponsor
Medical indications
Current status
Duration
FDA
approved
Glucocorticoid
Analogue
VBP15-003
ReveraGen BioPharma,
Inc.
Duchenne muscular
dystrophy
Phase2, completed
2019
No
Hepcidin
Lexaptepid pegol
(NOX-H94)
NOXXON Pharma AG
Anemia
Phase1/2, completed
2014-2015
No
Oxytocin
Oxytocin
Stanford University
Pregancy;exogenous
administration of
oxytocin during
childbirth to various
neurological disorders
later in the offspring’s
life
Preclinical,completed 2017
No
PDGF
E10030 (Anti-PDGF
Pegylated Aptamer)
Ophthotech Corporation
Macular degeneration
(AMD).
Phase2, completed
2010
No
PDGF-B
E10030-0039(Fovista) Retinal Consultants of
Arizona
Age-related macular
degeneration.
Phase 1,complete
2014
No
VEGF
EYE001 (Anti-VEGF
Pegylated Aptamer)
Eye Institute (NEI)
Advanced Ocular
Disease of Von
Hippel-Lindau (VHL)
Disease
Phase1, completed
2003-2005
No
EOP1004B
Eyetech Pharmaceuticals Neovascular AMD
Phase2/3, completed
2001
No
(continued)